This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in France
This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Italy; incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Spain; incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in the United Kingdom (U.K.); incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Italy; incidence and prevalence figures are compared with those of the Benelux countries
This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Spain
This report presents the prevalence and number of hospital discharges in the UnitedStates (U.S.) as well as the surgical procedure volumes for selected cardiovascular/thoracic diseases/disorders.
This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected musculoskeletal diseases/disorders.
This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected neurological diseases/disorders.
The scope of this report includes tissue-engineered skin replacements and substitutes (i.e., epidermal equivalents, dermal equivalents, and multilayer equivalents) and active wound repair modulators.
Approximately 16.3 million adults in the United States (U.S.) suffer from coronaryheart disease (CHD), a type of cardiovascular disease that is associated with areduction in blood flow through the vasculature of the heart (ischemic heart disease).
Discoveries in molecular medicine in recent years have allowed researchers to study the genetic/chromosomal alterations that trigger the transformation of normal cells into malignant cells, which ultimately has led to the understanding that cancer—of which there are more than 100 forms—is a disease of the cellular genome.
The scope of this report includes compression therapy products (e.g., compression bandages, compression stockings, and pneumatic compression devices) and pressure reduction and relief products (e.g., specialty/integrated beds, mattress replacements, and mattress overlays).
This report presents an overview of the most common types of treatment for the benign uterine conditions of menorrhagia and uterine fibroids/polyps; among these therapies are dilation and curettage, hysterectomy, hysteroscopy, and myomectomy. Market and competitive analyses for the medical devices used in these treatments also are presented.
The United States (U.S.) market for orthopedic biomaterials for bone repair and regeneration, as covered by the scope of this report
Prosthetic vascular grafts, made of synthetic or biological materials, are used to bypass or replace segments of blood vessels in kidney failure patients requiring hemodialysis access as well as those undergoing treatment for aneurysms or vascular occlusions.
The United States (U.S.) market for orthopedic biomaterials, as covered by the scope of this report, comprises bioresorbable fixation devices, visco supplementation products, cartilage repair and regeneration technologies.
This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the EU country of France.
This report provides analyses of products, markets, and competitors in the United States (U.S.) market for osteoporosis management products.
This report presents market and competitive analyses for selected leading contraceptive and fertility products as well as an overview of the most common types of contraceptives and fertility drugs/treatments available to women in the United States (U.S.) for reproductive management.
This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union country of Germany.
The intensity and high acuity of the critical care environment, combined with the shortage of experienced registered nurses, means that noninvasive and minimally invasive patient monitoring products will be in great demand during the forecast period covered by this report.
This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union country of Spain.
At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)
Areas covered: Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized.
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold
Macitentan is a novel dual endothelin receptor antagonist (ERA)
showing sustained receptor occupancy
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!